Annexon, Inc.

88 articles about Annexon, Inc.

• Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - April 16, 2024

  4/16/2024

  Annexon, Inc. announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

• Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - March 18, 2024

  3/18/2024

  Annexon, Inc. announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan.

• Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - February 20, 2024

  2/20/2024

  Annexon, Inc. announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan.

• 

  6 Neuro Data Readouts to Watch in the First Half of 2024

  1/22/2024

  From ALS to depression to Huntington’s disease, many neuroscience-focused companies are anticipating key data over the next few months.

• Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

  1/8/2024

  Annexon, Inc. outlined its strategic priorities for 2024 with late-stage clinical milestones, including ANX005 for Guillain-Barré syndrome, ANX007 for geographic atrophy and its first-in-kind oral small molecule complement inhibitor, ANX1502, for a range of autoimmune indications.

• Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

  12/27/2023

  Annexon, Inc. announced that Douglas Love, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. PT in San Francisco.

• Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

  12/20/2023

  Annexon, Inc. announced the pricing of an underwritten public offering of 25,035,000 shares of its common stock and pre-funded warrants to purchase 18,379,861 shares of common stock.

• Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - December 18, 2023

  12/18/2023

  Annexon, Inc. announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

• Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

  11/22/2023

  Annexon, Inc. announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at 2:10 p.m. ET in Miami.

• Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results

  11/13/2023

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, highlighted portfolio progress and reported third quarter 2023 financial results.

• Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference

  11/9/2023

  Annexon, Inc. announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 2023 Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 10:30 a.m. GMT in London.

• Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy

  10/24/2023

  Annexon, Inc. announced that the European Medicines Agency has granted Priority Medicine designation to ANX007 for the treatment of geographic atrophy secondary to age-related macular degeneration.

• Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - October 18, 2023

  10/18/2023

  Annexon, Inc. announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

• Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)

  10/10/2023

  Annexon, Inc. announced that the European Medicines Agency granted orphan drug designation to ANX005 for the treatment of Guillain-Barré Syndrome.

• Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference

  9/19/2023

  Annexon, Inc. announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 8:10 a.m. ET in NYC.

• Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - September 18, 2023

  9/18/2023

  Annexon, Inc. announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan.

• Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results

  8/7/2023

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, highlighted recent progress across its business and portfolio of complement therapies and reported second quarter 2023 financial results.

• Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - August 02, 2023

  8/2/2023

  Annexon, Inc. announced that it has granted an equity inducement award to Jamie Dananberg, M.D., the company’s Chief Medical Officer, under the terms of the 2022 Employment Inducement Award Plan.

• Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy

  7/30/2023

  Annexon, Inc. presented results from the ongoing ARCHER trial in patients with geographic atrophy, underscoring ANX007’s potentially distinct neuroprotective mechanism of action and demonstration of consistent protection from vision loss.

• Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer

  7/27/2023

  Annexon, Inc. announced the appointment of Jamie Dananberg, M.D., as chief medical officer.